COLL Q4 2024 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$182M+21.5% YoY

Gross Profit

$98M54.0% margin

Operating Income

$38M20.9% margin

Net Income

$13M6.9% margin

EPS (Diluted)

$0.35

QoQ Revenue Growth

+14.2%

Cash Flow

Operating Cash Flow

$85M

Free Cash Flow

$84M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$1.4B

Stockholders' Equity

$229M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$182M	$150M	+21.5%
Gross Profit	$98M	$95M	+3.9%
Operating Income	$38M	$62M	-38.2%
Net Income	$13M	$32M	-60.8%

Revenue Segments

Belbuca

$107M36%

Xtampza ER

$96M32%

Nucynta IR

$49M17%

Nucynta ER

$37M12%

Symproic

$8M3%